ALTO-100, previously known as NSI-189 (NeuralStem Inc. 189), [3] is a drug described as a hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) …

NSI-189 是一個 實驗性藥物 （英语：experimental drug），由 Neuralstem, Inc. （英语：Neuralstem, Inc.） 開發的 抗抑鬱藥。用於治療 重性抑郁障碍 （MDD）， 認知障礙 以及 神 …

NSI-189 是一个 实验性药物 （英语：experimental drug），由 Neuralstem, Inc. （英语：Neuralstem, Inc.） 开发的 抗抑郁药。 用于治疗 重性抑郁障碍 （MDD）， 认知障碍 以及 神 …

2025年3月20日 · As a nootropic, NSI-189 enhances cognitive functions, with research showing NSI-189 benefits include improved memory formation, enhanced learning capacity, increased …

These results suggest that NSI-189 is effective as a safe adjunctive therapy, with most compelling antidepressant and procognitive benefits noted in patients with moderate depression.

NSI-189 is a novel, neurogenic compound independent of serotonin or norepinephrine reuptake inhibition pathways. The compound was discovered by systematic screening of a chemical …

Results from a preliminary proof of concept study suggests that NSI-189 may be capable of mitigating depressive symptoms and improve cognitive function in adults with DSM-5-defined …

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal …

ALTO-100，以前称为NSI-189 (最初由NeuralStem开发)是一种海马体神经发生刺激剂和间接脑源性神经营养因子 (BDNF) 调节剂，目前正在开发用于治疗重度抑郁症、双相抑郁症和创伤后应 …

Enhancing neurogenesis may be a powerful stroke therapy. Here, we tested in a rat model of ischemic stroke the beneficial effects of NSI-189, an orally active, new molecular entity (mol. …